Palvella Therapeutics (PVLA) Net Cash Flow (2016 - 2024)
Historic Net Cash Flow for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to $69.4 million.
- Palvella Therapeutics' Net Cash Flow rose 66173.34% to $69.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $87.6 million, marking a year-over-year increase of 255556.23%. This contributed to the annual value of $76.3 million for FY2024, which is 221248.86% up from last year.
- Per Palvella Therapeutics' latest filing, its Net Cash Flow stood at $69.4 million for Q4 2024, which was up 66173.34% from -$188000.0 recorded in Q3 2024.
- Palvella Therapeutics' 5-year Net Cash Flow high stood at $69.4 million for Q4 2024, and its period low was -$33.0 million during Q1 2022.
- Its 5-year average for Net Cash Flow is $3.5 million, with a median of $359500.0 in 2023.
- As far as peak fluctuations go, Palvella Therapeutics' Net Cash Flow soared by 148858.2% in 2021, and later tumbled by 123574.61% in 2022.
- Quarter analysis of 5 years shows Palvella Therapeutics' Net Cash Flow stood at $1.5 million in 2020, then crashed by 523.13% to -$6.4 million in 2021, then crashed by 83.76% to -$11.7 million in 2022, then skyrocketed by 177.69% to $9.1 million in 2023, then surged by 661.73% to $69.4 million in 2024.
- Its Net Cash Flow was $69.4 million in Q4 2024, compared to -$188000.0 in Q3 2024 and $10.5 million in Q2 2024.